Grace S Crowther1, Caroline H Chilton2, Chris Longshaw3, Sharie L Todhunter1, Duncan Ewin1, Jonathan Vernon1, Andreas Karas3, Mark H Wilcox4. 1. Leeds Institute of Biomedical and Clinical Sciences, Faculty of Medicine and Health, University of Leeds, Leeds, UK. 2. Leeds Institute of Biomedical and Clinical Sciences, Faculty of Medicine and Health, University of Leeds, Leeds, UK c.h.chilton@leeds.ac.uk. 3. Astellas Pharma EMEA, Chertsey, Surrey, UK. 4. Leeds Institute of Biomedical and Clinical Sciences, Faculty of Medicine and Health, University of Leeds, Leeds, UK Department of Microbiology, Leeds Teaching Hospitals NHS Trust, The General Infirmary, Leeds, UK.
Abstract
OBJECTIVES: Effects of two vancomycin extended-dosing regimens on microbiota populations within an in vitro gut model of simulated Clostridium difficile infection (CDI) were evaluated. METHODS: Two chemostat gut models were inoculated with faecal emulsion and clindamycin instilled to induce CDI. Simulated CDI was treated with vancomycin (125 mg/L four times daily, 7 days) followed by different vancomycin dosing extensions totalling 7 g (lower dose) or 9.5 g (higher dose) over 6 weeks in Model A and Model B, respectively. Microbiota populations, C. difficile vegetative cells and spores, cytotoxin, antimicrobial concentrations and vancomycin-tolerant enterococci (VTE) were measured every 1-2 days. RESULTS: In both models, vancomycin instillation caused a rapid decline in vegetative cells and cytotoxin, and declines in the Bacteroides fragilis group, bifidobacteria and clostridia populations to the lower limit of detection. Bifidobacteria failed to recover for the remainder of the experiment. B. fragilis group populations recovered to pre-dosing levels during the dosing extension in Model A and after dosing ceased in Model B. Recurrent CDI was observed on the penultimate day of Model B, but not Model A. VTE were observed throughout the experiment in both models, but populations increased during vancomycin instillation and post-vancomycin instillation. CONCLUSIONS: The two vancomycin extended-dosing regimens were efficacious in initial treatment of simulated CDI. Both had a prolonged deleterious effect on the indigenous gut microbiota, a factor that may contribute to recurrence; recurrence was observed only in Model B, although the potential for vegetative regrowth within Model A cannot be excluded. Vancomycin exposure appeared to select for VTE populations.
OBJECTIVES: Effects of two vancomycin extended-dosing regimens on microbiota populations within an in vitro gut model of simulated Clostridium difficileinfection (CDI) were evaluated. METHODS: Two chemostat gut models were inoculated with faecal emulsion and clindamycin instilled to induce CDI. Simulated CDI was treated with vancomycin (125 mg/L four times daily, 7 days) followed by different vancomycin dosing extensions totalling 7 g (lower dose) or 9.5 g (higher dose) over 6 weeks in Model A and Model B, respectively. Microbiota populations, C. difficile vegetative cells and spores, cytotoxin, antimicrobial concentrations and vancomycin-tolerant enterococci (VTE) were measured every 1-2 days. RESULTS: In both models, vancomycin instillation caused a rapid decline in vegetative cells and cytotoxin, and declines in the Bacteroides fragilis group, bifidobacteria and clostridia populations to the lower limit of detection. Bifidobacteria failed to recover for the remainder of the experiment. B. fragilis group populations recovered to pre-dosing levels during the dosing extension in Model A and after dosing ceased in Model B. Recurrent CDI was observed on the penultimate day of Model B, but not Model A. VTE were observed throughout the experiment in both models, but populations increased during vancomycin instillation and post-vancomycin instillation. CONCLUSIONS: The two vancomycin extended-dosing regimens were efficacious in initial treatment of simulated CDI. Both had a prolonged deleterious effect on the indigenous gut microbiota, a factor that may contribute to recurrence; recurrence was observed only in Model B, although the potential for vegetative regrowth within Model A cannot be excluded. Vancomycin exposure appeared to select for VTE populations.
Authors: Myreen E Tomas; Thriveen S C Mana; Brigid M Wilson; Michelle M Nerandzic; Samira Joussef-Piña; Miguel E Quiñones-Mateu; Curtis J Donskey Journal: Antimicrob Agents Chemother Date: 2018-04-26 Impact factor: 5.191
Authors: Hannah C Harris; Emma L Best; Charmaine Normington; Nathalie Saint-Lu; Frédérique Sablier-Gallis; Jean de Gunzburg; Antoine Andremont; Mark H Wilcox; Caroline H Chilton Journal: Antimicrob Agents Chemother Date: 2020-12-16 Impact factor: 5.191
Authors: Ines B Moura; Charmaine Normington; Duncan Ewin; Emma Clark; Mark H Wilcox; Anthony M Buckley; Caroline H Chilton Journal: BMC Microbiol Date: 2020-01-02 Impact factor: 3.605
Authors: Nigel George Ternan; Nicola Diana Moore; Deborah Smyth; Gordon James McDougall; James William Allwood; Susan Verrall; Christopher Ian Richard Gill; James Stephen Gerard Dooley; Geoff McMullan Journal: Sci Rep Date: 2018-11-12 Impact factor: 4.379